UA41341C2 - СПОСІБ ОДЕРЖАННЯ ФІНАСТЕРИДУ, 17<font face="Symbol">b</font>-[N-ТРЕТ-БУТИЛКАРБАМОЇЛ]-4-АЗА-5<font face="Symbol">a</font>-АНДРОСТ-1-ЕН-3-ОН У ПОЛІМОРФНІЙ ФОРМІ I ТА ІI, СПОСОБИ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ) - Google Patents

СПОСІБ ОДЕРЖАННЯ ФІНАСТЕРИДУ, 17<font face="Symbol">b</font>-[N-ТРЕТ-БУТИЛКАРБАМОЇЛ]-4-АЗА-5<font face="Symbol">a</font>-АНДРОСТ-1-ЕН-3-ОН У ПОЛІМОРФНІЙ ФОРМІ I ТА ІI, СПОСОБИ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ)

Info

Publication number
UA41341C2
UA41341C2 UA95058438A UA95058438A UA41341C2 UA 41341 C2 UA41341 C2 UA 41341C2 UA 95058438 A UA95058438 A UA 95058438A UA 95058438 A UA95058438 A UA 95058438A UA 41341 C2 UA41341 C2 UA 41341C2
Authority
UA
Ukraine
Prior art keywords
font
symbol
preparing
face
finasteride
Prior art date
Application number
UA95058438A
Other languages
English (en)
Russian (ru)
Inventor
X. Доллінг Ульф
Х. Доллинг Ульф
A. МакКаулі Джеймс
А. МакКаули Джеймс
Дж. Варсолона Річард
Дж. Варсолона Ричард
Original Assignee
Мерк Енд Ко., Інк.
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26681536&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA41341(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Енд Ко., Інк., Мерк Энд Ко., Инк. filed Critical Мерк Енд Ко., Інк.
Publication of UA41341C2 publication Critical patent/UA41341C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00—Details of television systems
    • H04N5/74—Projection arrangements for image reproduction, e.g. using eidophor
    • H04N5/7416—Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal
    • H04N5/7458—Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal the modulator being an array of deformable mirrors, e.g. digital micromirror device [DMD]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
  • Dental Preparations (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Спосіб одержання фінастериду формули (2): Спосіб включає 1) контакт складного ефіру формули (1): де R є лінійним або розгалуженим (С1-С10) алкілом, з т-бутиламіномагнійгалогенідом, де молярне співвідношення т-бутиламіномагнійгалогеніду і складного ефіру складає, щонайменше, близько 2:1, в інертному органічному розчиннику в атмосфері інертного газу; 2) витримку реакційної суміші при температурі, щонайменше, 10°С; і 3) виділення фінастериду формули (2).
UA95058438A 1992-11-19 1993-11-05 СПОСІБ ОДЕРЖАННЯ ФІНАСТЕРИДУ, 17<font face="Symbol">b</font>-[N-ТРЕТ-БУТИЛКАРБАМОЇЛ]-4-АЗА-5<font face="Symbol">a</font>-АНДРОСТ-1-ЕН-3-ОН У ПОЛІМОРФНІЙ ФОРМІ I ТА ІI, СПОСОБИ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ) UA41341C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97853592A 1992-11-19 1992-11-19
US08/010,734 US5468860A (en) 1992-11-19 1993-01-29 New finasteride processes
PCT/US1993/010659 WO1994011387A2 (en) 1992-11-19 1993-11-05 A process for the production of finasteride

Publications (1)

Publication Number Publication Date
UA41341C2 true UA41341C2 (uk) 2001-09-17

Family

ID=26681536

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95058438A UA41341C2 (uk) 1992-11-19 1993-11-05 СПОСІБ ОДЕРЖАННЯ ФІНАСТЕРИДУ, 17<font face="Symbol">b</font>-[N-ТРЕТ-БУТИЛКАРБАМОЇЛ]-4-АЗА-5<font face="Symbol">a</font>-АНДРОСТ-1-ЕН-3-ОН У ПОЛІМОРФНІЙ ФОРМІ I ТА ІI, СПОСОБИ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ)

Country Status (33)

Country Link
US (3) US5468860A (uk)
EP (3) EP0599376B2 (uk)
JP (2) JPH07110875B2 (uk)
CN (1) CN1058018C (uk)
AT (2) ATE177112T1 (uk)
AU (1) AU658774B2 (uk)
BG (2) BG62362B1 (uk)
CA (1) CA2103107C (uk)
CY (1) CY2135B1 (uk)
CZ (3) CZ301160B6 (uk)
DE (4) DE69317856T2 (uk)
DK (2) DK0599376T4 (uk)
DZ (1) DZ1733A1 (uk)
ES (2) ES2052476T5 (uk)
FI (4) FI107450B (uk)
GR (4) GR940300045T1 (uk)
HK (1) HK1008338A1 (uk)
HR (2) HRP931410B1 (uk)
HU (2) HU216195B (uk)
IL (1) IL107574A (uk)
IS (2) IS1692B (uk)
LV (2) LV12212B (uk)
MX (1) MX9307222A (uk)
MY (2) MY110410A (uk)
NO (3) NO305912B1 (uk)
PH (1) PH31120A (uk)
RO (2) RO115164B1 (uk)
RU (1) RU2120445C1 (uk)
SI (1) SI9300603B (uk)
SK (2) SK286488B6 (uk)
TW (1) TW257766B (uk)
UA (1) UA41341C2 (uk)
WO (1) WO1994011387A2 (uk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
IT1270660B (it) * 1994-10-13 1997-05-07 Poli Ind Chimica Spa Procedimento microbiologico per la preparazione di 3-oxo-4-azasteroidi-17beta-carbossi sostituiti e uso dei prodotti come inibitori dell'enzima 5alfa-riduttasi
US5670643A (en) * 1995-03-16 1997-09-23 Glaxo Wellcome Inc. Method for preparing finasteride
US5585383A (en) * 1995-05-03 1996-12-17 Merck & Co., Inc. Process for crystallizing a 4-azasteroid 5alpha-reductase inhibitor
WO1997010217A1 (en) * 1995-09-15 1997-03-20 Merck & Co., Inc. 4-azasteroids for treatment of hyperandrogenic conditions
GB2338234B (en) * 1998-06-10 2000-05-03 Torcan Chemical Ltd Preparation of finasteride
ES2153789B1 (es) * 1999-07-05 2001-10-16 Raga Consultores S L Procedimiento para la obtencion de 178-(n-terc-butlcarbamoil)-3-ona-4-aza-esteroides
EP1228084A1 (en) * 1999-11-01 2002-08-07 TORCAN CHEMICAL Ltd Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts
SK2732003A3 (en) * 2000-09-07 2004-01-08 Reddys Lab Ltd Dr Novel polymorphic form of 17-beta-(N-ter.butyl carbamoyl)-4-aza- 5-alpha-androst-1-en-3-one and a process for preparing it
MXPA03002031A (es) * 2000-09-07 2004-12-13 Reddys Lab Ltd Dr Forma polimorfica novedosa de 17-beta-(n-tercbutil carbamoil)-4-aza-5-alfa-androst-1-en-3-ona y proceso para preparar la misma.
NZ525116A (en) * 2000-09-07 2004-11-26 Dr Novel polymorphic form of 17- beta -(N-ter.butyl carbamoyl)-4-AZA-5- alpha -androst-1-en-3-one and a process for preparing it
KR100415858B1 (ko) * 2001-09-22 2004-01-24 한미약품 주식회사 17베타-(엔-3차-부틸카바모일)-3-온 스테로이드 화합물의제조방법
CN100428897C (zh) * 2002-08-16 2008-10-29 浙江寿峰堂生物工程有限公司 抗疲劳改善亚健康的保健食品及其制备方法
ES2206065B1 (es) * 2002-10-31 2005-08-16 Ragactives, S.L. Procedimiento para la obtencion de la forma polimorfica i de finasterida.
WO2004083230A1 (en) * 2003-03-19 2004-09-30 Hetero Drugs Limited Novel crystalline forms of finasteride
ATE406376T1 (de) * 2003-07-03 2008-09-15 Cipla Ltd Verfahren zur herstellung von finasterid form i
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
US20070167477A1 (en) * 2006-01-13 2007-07-19 Mandava Venkata Naga Brahmeswa Processes to prepare finasteride polymorphs
US7531658B2 (en) * 2006-01-20 2009-05-12 Apotex Pharmachem Inc. Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
WO2007089267A1 (en) 2006-02-03 2007-08-09 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US9004752B2 (en) * 2008-05-05 2015-04-14 Abbvie, Inc. Method for evaluating the solubility of a crystalline substance in a polymer
CA2750636C (en) 2009-01-23 2017-07-25 Jr Chem, Llc Rosacea treatments and kits for performing them
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
NZ225100A (en) * 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US5084574A (en) * 1988-04-18 1992-01-28 Merck & Co., Inc. Dehydrogenation process
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
EP0461930B1 (en) * 1990-06-15 1995-09-13 Merck & Co. Inc. A crystallization method to improve crystal structure and size
EP0462662A3 (en) * 1990-06-20 1992-08-19 Merck & Co. Inc. 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5120847A (en) † 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
US5091534A (en) 1990-08-27 1992-02-25 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
CA2050824A1 (en) * 1990-09-24 1992-03-25 John M. Williams Process for making 3-oxo-4-aza-androst-1-ene 17-.beta.-ketones
US5061801A (en) * 1990-09-24 1991-10-29 Merck & Co., Inc. Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes

Also Published As

Publication number Publication date
ES2052476T5 (es) 2008-11-01
DZ1733A1 (fr) 2002-02-17
IS1671B (is) 1997-12-19
PH31120A (en) 1998-02-23
NO307888B1 (no) 2000-06-13
SK65995A3 (en) 1995-10-11
IS4286A (is) 1994-05-20
LV12460A (lv) 2000-04-20
NO990468D0 (no) 1999-02-01
CN1090583A (zh) 1994-08-10
SK286488B6 (sk) 2008-11-06
TW257766B (uk) 1995-09-21
LV12212A (lv) 1999-01-20
RU95112521A (ru) 1997-02-10
CA2103107A1 (en) 1994-05-20
WO1994011387A3 (en) 1994-09-29
NO307609B1 (no) 2000-05-02
US5886184A (en) 1999-03-23
GR950300043T1 (en) 1995-07-31
EP0823436A3 (en) 1998-11-25
ES2052476T3 (es) 1998-06-16
NO990468L (no) 1995-05-19
JPH07110875B2 (ja) 1995-11-29
NO305912B1 (no) 1999-08-16
GR940300045T1 (en) 1994-07-29
ATE164850T1 (de) 1998-04-15
WO1994011387A2 (en) 1994-05-26
ES2072848T1 (es) 1995-08-01
HRP20000295A2 (en) 2000-08-31
GR3029554T3 (en) 1999-06-30
IL107574A0 (en) 1994-02-27
DK0599376T4 (da) 2008-07-28
BG99637A (bg) 1996-04-30
DE69323754T2 (de) 1999-10-07
EP0655458A2 (en) 1995-05-31
AU658774B2 (en) 1995-04-27
NO992580D0 (no) 1999-05-28
ATE177112T1 (de) 1999-03-15
HU216195B (hu) 1999-05-28
CZ287842B6 (en) 2001-02-14
NO951986D0 (no) 1995-05-19
CA2103107C (en) 2010-09-28
EP0655458A3 (en) 1996-07-10
US5652365A (en) 1997-07-29
EP0599376A2 (en) 1994-06-01
CY2135B1 (en) 2002-05-21
FI20040559A (fi) 2004-04-21
BG103170A (en) 1999-09-30
SK281765B6 (sk) 2001-07-10
DE69317856D1 (de) 1998-05-14
IS4094A (is) 1994-05-20
FI107450B (fi) 2001-08-15
HU210535A9 (en) 1995-04-28
BG62362B1 (bg) 1999-09-30
RU2120445C1 (ru) 1998-10-20
DE69317856T2 (de) 1998-11-05
EP0599376A3 (en) 1994-09-28
BG64464B1 (bg) 2005-03-31
LV12212B (en) 1999-03-20
FI114215B (fi) 2004-09-15
ES2072848T3 (es) 1999-05-01
JP2742409B2 (ja) 1998-04-22
GR3026577T3 (en) 1998-07-31
MY110411A (en) 1998-05-30
AU5078793A (en) 1994-06-16
CN1058018C (zh) 2000-11-01
DE655458T1 (de) 1995-11-30
EP0655458B1 (en) 1999-03-03
CZ301160B6 (cs) 2009-11-18
EP0599376B1 (en) 1998-04-08
JPH06199889A (ja) 1994-07-19
SI9300603B (sl) 2004-06-30
FI20010289A (fi) 2001-02-15
RO115164B1 (ro) 1999-11-30
HK1008338A1 (en) 1999-05-07
DE69323754D1 (de) 1999-04-08
LV12460B (en) 2000-09-20
IL107574A (en) 2000-07-16
RO115165B1 (ro) 1999-11-30
MY110410A (en) 1998-05-30
CZ126895A3 (en) 1995-12-13
FI952422A (fi) 1995-05-18
MX9307222A (es) 1994-07-29
HRP931410B1 (en) 2000-06-30
NO951986L (no) 1995-05-19
CZ301191B6 (cs) 2009-12-02
ES2052476T1 (es) 1994-07-16
EP0823436A2 (en) 1998-02-11
SI9300603A (en) 1994-06-30
HRP20000295B1 (en) 2002-08-31
IS1692B (is) 1998-04-20
HUT66973A (en) 1995-01-30
EP0599376B2 (en) 2008-04-16
FI114800B (fi) 2004-12-31
FI116941B (fi) 2006-04-13
HRP931410A2 (en) 1996-06-30
HU9303275D0 (en) 1994-03-28
JPH09235294A (ja) 1997-09-09
US5468860A (en) 1995-11-21
FI952422A0 (fi) 1995-05-18
FI20010290A (fi) 2001-02-15
DK0655458T3 (da) 1999-09-27
DE599376T1 (de) 1994-12-08
NO307888B3 (no) 2000-06-13
NO992580L (no) 1995-05-19

Similar Documents

Publication Publication Date Title
UA41341C2 (uk) СПОСІБ ОДЕРЖАННЯ ФІНАСТЕРИДУ, 17&lt;font face=&#34;Symbol&#34;&gt;b&lt;/font&gt;-[N-ТРЕТ-БУТИЛКАРБАМОЇЛ]-4-АЗА-5&lt;font face=&#34;Symbol&#34;&gt;a&lt;/font&gt;-АНДРОСТ-1-ЕН-3-ОН У ПОЛІМОРФНІЙ ФОРМІ I ТА ІI, СПОСОБИ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ)
KR860004077A (ko) 7-할로-7-데옥시린코마이신, 클린다마이신 및 이들의 유사체의 제조방법
ES2119190T3 (es) Procedimiento para producir un compuesto de lignano.
ES2001342A6 (es) Un procedimiento para la preparacion de una composicion espesante a base de hidrocarbilsuccinatos de poli (oxialquileno).
AU633899B2 (en) Process for oxidizing saturated primary amines to oximes
ES8606381A1 (es) Un procedimiento para preparar un derivado de uridina.
DE3362908D1 (en) Process for preparing trithiocarbonic acid diesters
JPS5424831A (en) Preparation of silanol oligomer liquid
KR890701544A (ko) 스틸벤디카복실레이트 유도체의 제조방법
KR940002224A (ko) 2-클로로-5-아미노메틸-피리딘의 제조방법
JPS567796A (en) Organic silicon compound
BR8600260A (pt) Processo para a preparacao de triacetoxissilanas a partir de tris(amino)silanas
JPS542300A (en) Methdo and apparatus for vapor phase growth of magnespinel
ES483249A1 (es) Procedimiento para la obtencion de diciclopentilen(2,2&#39;-bis (4-alquil-6-t-butilfenoles).
KR850006188A (ko) 스피로-3-헤테로-아졸리딘디온의 제조방법
CA1260003C (uk)
JPS6445393A (en) Estradiol derivative
KR840006208A (ko) 7-아닐리노이소퀴놀린-5,8-퀴논의 제조방법
KR920019795A (ko) 5, 6, 11, 12-테트라티오테트라센의 제조방법
ES440495A1 (es) Procedimiento para la preparacion de poli-(alquilimino-ala- nos).
EP0619294A4 (en) PROCESS FOR THE PRODUCTION OF 1-PHENOXY-2-AMINOPROPANE.
JPS57200340A (en) Process for selective n-substitution of aromatic aminohydroxy compound
JPS55141448A (en) Separation of aniline chlorosulfate or alpha-naphthylamine chlorosulfate
KR940002216A (ko) 2-((2,6-디클로로페닐)아미노)페닐아세톡시아세트산의 제조방법
KR880007437A (ko) 카르복실산 아미드의 제조 방법